Summit Therapeutics to test lead cancer drug with Pfizer ADCs

Summit Therapeutics (NASDAQ:SMMT) has entered a clinical trial collaboration to evaluate its cancer drug, ivonescimab, in combination with Pfizer (NYSE:PFE) antibody drug conjugates across multiple solid tumor settings.

Under the pact, Summit will provide ivonescimab for use in the proposed studies, while